Biosimilars And The Need For Real-World Evidence
This article was originally published in SRA
The success of biosimilars will depend on a range of factors, including local policies on interchangeability, harmonization of naming conventions, reimbursement decisions, and physician adoption. Real-world evidence will help to support data generated by clinical trials and fill the evidence gap for doctors, patients and payers, say Jaclyn Bosco and Nancy Dreyer.
Register for our free email digests: